Prognostic value of CA 15.3 kinetics for metastatic breast cancer

International Journal of Biological Markers

Volumn 17, Issue 4, 2002, Pages 231-238

  De La Lande, B ^a   Hacene, K ^a   Floiras, J L ^a   Alatrakchi, N ^a   Pichon, M F ^a  

^a CENTRE RENÉ HUGUENIN   (France)

Author keywords

Breast cancer metastases; Breast cancer prognosis; CA 15.3

Indexed keywords

CA 15-3 ANTIGEN; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIRUBICIN; ESTROGEN RECEPTOR; FLUORODEOXYGLUCOSE F 18; FLUOROURACIL; HORMONE; METHOTREXATE; PROGESTERONE RECEPTOR; TAMOXIFEN;

ADULT; AGED; ARTICLE; ASSAY; BREAST CANCER; BREAST METASTASIS; BREAST TUMOR; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; IMAGING; KAPLAN MEIER METHOD; KINETICS; LYMPH NODE DISSECTION; MAJOR CLINICAL STUDY; MULTIVARIATE ANALYSIS; PARTIAL MASTECTOMY; PROGNOSIS; STATISTICAL ANALYSIS; STATISTICAL MODEL; STATISTICAL SIGNIFICANCE; SURVIVAL RATE; TUMOR VOLUME;

EID: 12244313474     PISSN: 03936155     EISSN: None     Source Type: Journal    
DOI: 10.5301/JBM.2008.2371     Document Type: Article

References (22)

1. Cheung KL, Graves CRL, Robertson JFR. Tumour marker measurement in the diagnosis and monitoring of breast cancer. Cancer Treat Rev 2000; 26: 91-102.
2. Stearns V, Yamauchi H, Hayes DF. Circulating tumor markers in breast cancer: Accepted utilities and novel prospects. Breast Cancer Res Treat 1998; 52: 239-59.
3. Ebeling FC, Schmitt UM, Untch M, et al. Tumour markers CEA and CA 15.3 as prognostic factors in breast cancer-univariate and multivariate analysis. Anticancer Res 1999; 19: 2545-2550.
4. Schering SG, Sherry F, McDermott EW, O'Higgins NJ, Duffy MJ. Preoperative CA 15.3 concentrations predict outcome of patients with breast carcinoma. Cancer 1998; 83: 2521-7.
5. Colomer R, Ruibal A, Genolla A, et al. Circulating CA 15.3 levels in the postsurgical follow-up of breast cancer patients and in non-malignant diseases. Breast Cancer Res Treat 1989; 13: 123-33.
6. Vizcarra E, Lluch A, Cibrian R, et al. Value of CA 15.3 in breast cancer and comparison with CEA and TPA: A study of specificity in disease-free follow-up patients and sensitivity in patients at diagnosis of the first metastasis. Breast Cancer Res Treat 1996; 37: 209-16.
7. Pecking AP, Mechelany-Corone C, Bertrand-Kermogant F et al. Detection of occult disease in breast cancer using fluorodeoxyglucose camera-based positron emission tomography. Clin Breast Cancer 2001; 2: 229-34.
8. Molina R, Jo J, Filella X, Zanon G, et al. c-erbB-2 CEA and CA 15.3 serum levels in the early diagnosis of recurrence in breast cancer patients. Anticancer Res 1999; 19: 2551-6.
9. Hermanek P, Sobin LH, eds. Union International Contre le Cancer (UICC): TNM Classification of Malignant Tumours, 4th ed., revised 1992. Berlin: Springer-Verlag, 1987.
10. Bloom HJG, Richardson WW. Histological grading and prognosis in breast cancer. Br J Cancer 1957; 11: 339-77.
11. Kaplan EL, Meier P. Non parametric estimation for incomplete observations. J Am Stat Assoc 1958; 53: 457-81.
12. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 1966; 50: 163-70.
13. Cox DR. Regression models and life tables. J R Stat Soc 1972; 34: 187-200.
14. Jager W. The early detection of disseminated (metastasized) breast cancer by serial tumour marker measurements. Eur J Cancer Prev 1993; 2: 133-9.
15. Kovner F, Merimsky O, Hareuveni M, Wigler N, Chaitchik: Treatment of disease-negative but mucin-like carcinoma-associated antigen-positive breast cancer patients with tamoxifen: Preliminary results of a prospective controlled randomized trial. Cancer Chemother Pharmacol 1994; 35: 80-3.
16. Nicolini A, Anselmi L, Michelasi C, Carpi A: Prolonged survival by 'early' salvage treatment of breast cancer patients: A retrospective 6-year study. Br J Cancer 1997; 76: 1106-11.
17. Berruti M, Tampellini M, Torta M, Buniva T, Gorzegno G, Dogliotti L: Prognostic value in predicting overall survival of two mucinous markers: CA 15.3 and CA 125 in breast cancer patients at first relapse of disease. Eur J Cancer 1994; 30A: 2082-4.
18. Tampellini M, Berruti A, Gerbino A, et al. Relationship between CA 15.3 serum levels and disease extent in predicting overall survival of breast cancer patients with newly diagnosed metastatic disease. Br J Cancer 1997; 75: 698-702.
19. De Vita VT: The relationship between tumor mass and resistance to chemotherapy. Cancer 1983; 51: 1209-20.
20. Nicolini A, Carpi A: Postoperative follow-up of breast cancer patients: Overview and progress in the use of tumor markers. Tumour Biol 2000; 21: 235-48.
21. Tampellini M, Berruti A, Gorzegno G, et al. Relationship between estrogen receptor (ER) status in primary breast cancer specimen and serum CA 15.3 levels at first relapse of disease. Proc ASCO 1997; 16: A679.
22. Seregni E, Botti C, Bajetta E, et al. Hormonal regulation of MUC1 expression. Int J Biol Markers 1999; 14: 29-35.